Moderna to Present Data on mRNA Therapeutics at ICIEM 2025

Moderna has announced that five abstracts on its investigational mRNA therapeutics will be presented at the 2025 International Congress of Inborn Errors of Metabolism. The presentations will focus on its propionic acidemia, methylmalonic acidemia, and Glycogen Storage Disease Type 1a programs. This is the first time Moderna will present data at a scientific congress for MMA and GSD1a.

Moderna, Inc. (NASDAQ: MRNA) has announced that five abstracts on its investigational mRNA therapeutics will be presented at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM). The presentations will focus on the company's propionic acidemia (PA), methylmalonic acidemia (MMA), and Glycogen Storage Disease Type 1a (GSD1a) programs, marking the first time Moderna will present data at a scientific congress for MMA and GSD1a [1].

The presentations, scheduled for September 2-6, 2025, in Kyoto, Japan, include three oral presentations and two poster presentations. The oral presentations will cover clinical burden data for propionic acidemia in Japan, interim data from Phase 1/2 studies for MMA and GSD1a, and final results from the dose-escalation cohorts of the mRNA-3927-P101 study for PA. The poster presentations will feature model-informed dose selection for a pivotal MMA study and interim data from the Phase 1/2 Ba1ance Study for GSD1a [2].

These presentations demonstrate Moderna's strategic expansion into rare diseases, leveraging its mRNA platform technology beyond vaccines into therapeutics. The company is addressing significant unmet medical needs with limited treatment options. The presentations will provide validation and visibility for these development programs within the scientific and medical communities specialized in metabolic disorders.

Moderna's diversification into rare diseases is a strategic move that could open up new revenue streams beyond its established COVID-19 vaccine business. While these programs are still in early to mid-stage clinical development, their advancement represents an important diversification of Moderna's pipeline.

References:
[1] https://www.stocktitan.net/news/MRNA/moderna-announces-data-to-be-presented-at-the-2025-international-3ddgvnfi7m8o.html
[2] https://www.newswire.com/news/moderna-announces-data-to-be-presented-at-the-2025-international-congress-of